UCB S.A. (UCBJY)


Other OTC - Other OTC Delayed Price. Currency in USD
40.63-0.14 (-0.33%)
At close: 3:47 PM EDT
People also watch:
DSNKYTKPYYESALYMKGAYALPMY
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open40.93
Prev Close40.77
Bid0.00 x
Ask0.00 x
Day's Range40.63 - 40.93
52wk Range40.63 - 41.60
1y Target EstN/A
Market Cap15.3B
P/E Ratio (ttm)20.76
Beta0.49
Volume646
Avg Vol (3m)1,428
Dividend & Yield0.63 (1.56%)
Earnings DateN/A
Trade prices are not sourced from all markets
  • UCB SA :UCBJY-US: Earnings Analysis: For the six months ended June 30, 2016 : August 22, 2016
    Capital Cube6 days ago

    UCB SA :UCBJY-US: Earnings Analysis: For the six months ended June 30, 2016 : August 22, 2016

    Categories: Yahoo Finance Get free summary analysis UCB SA reports financial results for the half-year ended June 30, 2016. We analyze the earnings along side the following peers of UCB SA – Shire PLC Sponsored ADR, Amgen Inc., Pfizer Inc., Biogen Inc., Novartis AG Sponsored ADR and Catalyst Pharmaceuticals, Inc. (SHPG-US, AMGN-US, PFE-US, BIIB-US, NVS-US and CPRX-US) that ... Read more (Read more...)

  • Capital Cubelast month

    UCB SA :UCBJY-US: Earnings Analysis: For the six months ended December 31, 2015 : July 26, 2016

    Click here to see latest analysisUCB SA reports financial results for the half-year ended December 31, 2015.We analyze the earnings along side the following peers of UCB SA – Biogen Inc. and Novartis AG Sponsored ADR (BIIB-US and NVS-US) that have also reported for this period.HighlightsSummary numbers: Revenues of USD 2,151.22 million, Net Earnings of […] (Read more...) The post UCB SA :UCBJY-US: Earnings Analysis: For the six months ended December 31, 2015 : July 26, 2016 appeared first on CapitalCube.

  • PR Newswirelast month

    Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA

    THOUSAND OAKS, Calif. and BRUSSELS, July 22, 2016 /PRNewswire/ -- Amgen (AMGN) and UCB (Euronext Brussels: UCB) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. "Osteoporosis is a large public health problem yet is often overlooked, even in patients who have already experienced an osteoporotic fracture,"1,2 said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. The BLA for romosozumab is based on data from the pivotal Phase 3 placebo-controlled FRActure study in postemenopausal woMen with ostEoporosis (FRAME) in approximately 7,200 patients.